The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma
Patients with follicular lymphoma who require therapy and have been previously untreated are eligible for this non-randomized, phase II study evaluating up front therapy with CHOP-R x 3 cycles followed by zevalin and 4 additional weeks of rituxan.The complete response will be determined by combining IWC criteria and PET scanning.Secondary objectives include PET-CT conversion rate, frequency and severity of adverse events, duration of complete remission and time to next lymphoma therapy.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
CHOP-R x 3 cycles followed by zevalin and extended rituximab
UPMC Cancer Centers
Pittsburgh, Pennsylvania, United States
Complete response rate
Time frame: May 2007,May 2008, May2009, May 2010
PET-CT conversion rate
Time frame: May2007
Frequency and severity of adverse events
Time frame: May 2007
Duration of complete response
Time frame: May 2007,May 2008, May 2009, May 2010
Time to next lymphoma therapy
Time frame: May 2207,May2008,May2009, May2010
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.